New AKU treatment comes closer to commercialisation

Nitisinone is probably the biggest source of hope for alkaptonuria (AKU) patients right now. Research efforts under the DevelopAKUre project are bringing its commercialisation within reach. DevelopAKUre (Clinical Development of Nitisinone for Alkaptonuria), the project investigating nitisinone supported by the AKU Society and coordinated by the Royal Liverpool and Broadgreen University, is close to completing its third study.